IN 1130

Product Description

IN 1130 is a potent and selective inhibitor of TGF-β type I receptor (ALK5). Inhibits Smad-2 phosphorylation (IC₅₀ = 5.3 nM). Exhibits selectivity over a panel of 27 serine/ threonine and tyrosine kinases including P38α. Attenuates TGFβ/Smad signaling, cell migration, invasion, lung metastasis and increases survival of mice in 4TI in vivo models. Suppresses renal fibrosis in obstructive nephropathy in vivo models.

Solubility

Preparing Stock Solutions for IN 1130

The following data is based on the product molecular weight 420.47

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.38 mL	11.89 mL	23.78 mL
5 mM	0.48 mL	2.38 mL	4.76 mL
10 mM	0.24 mL	1.19 mL	2.38 mL
50 mM	0.05 mL	0.24 mL	0.48 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Lee Effect of IN-1130, a small molecule inhibitor of transforming growth factor-beta type I receptor/AVNreceptor-like kinase-5, on prostate cancer cells. J.Urol. 2008 PMID: 18951571
• Park An novel inhibitor of TGF-beta type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition. Cancer Lett. 2014 PMID: 24887560
• Moon IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int. 2006 PMID: 16929250